‘Game-changer’ GLP-1s could fix America’s obesity crisis—but 2 inequalities stand in the way
Wells Fargo Industry Insights' Robin Wenzel says the drugs are rewriting healthcare economics, but the math doesn't "pencil out" too often.
We haven't written up this one. Fortune has the full story — the link below goes straight to it.